been available in these groups of vulnerable people. In this retrospective-matched cohort study with diff erence-in-diff erence methods, we investigated the 4-year FF risk in older patients (≥60) and patients with comorbidities.
We used the Clinical Practice Research Datalink, a database of primary care electronic medical records linked to hospital records. Th e sample included 86,469 patients receiving PPIs for ≥1 year and 86,469 age-and gender-matched controls, registered with a primary care practice in England between April 1997 and March 2014.
PPIs (esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole) were identifi ed in the electronic prescribing data and analyzed as a class, regardless of dosage. Th e date of the fi rst PPI prescription for the treated member of each matched pair was deemed the pair's index date.
FFs, were defi ned by hospitalization for new spine, hip, wrist, humerus, pelvis, ankle and rib fracture, coded using ICD-10. Patients with FFs within 3 months before their fi rst PPI prescription were excluded, to avoid bias ( 2 ).
Cox's regressions were used to compare FF risk during the 4 years before (pretreatment period) and aft er (treatment period) index date. According to the Prior Event Rate Ratio (PERR) approach ( 3 ), a diff erence-in-diff erence method, hazard ratios in the pre-treatment period were used to correct the treatment period hazard ratios. PERR was used to address both measured and unmeasured confounding, the latter being a major caveat in the interpretation of current evi dence ( 4 ) .
Results were stratifi ed by age (60-74, 75-84, and ≥85) and comorbidity (Charlson comorbidity index, 0 and ≥1). Numbers needed to harm (NNHs) were also calculated ( 5 ). Subgroups were compared using confi dence intervals since interactions cannot be tested using PERR.
Th e mean age was 71.9 (±7.9) years. FF rates in people aged ≥60 and those 60-74, 75-84, and ≥85 were 11.7, 7.3, 18.5, and 33 per 1000 person-years, respectively.
Diff erences at index date between treatment groups ( 
Proton-Pump Inhibitors and Fragility Fractures in Vulnerable Older Patients
To the Editor: Proton Pump Inhibitors (PPIs) taken for ≥1 year have been linked to increased fragility fracture (FF) risk, prompting the US FDA to issue a related warning. Th e oldest old (≥85) and patients with comorbidities may be at greater risk ( 1 ); however, little or no evidence has sive metastases indicative of aggressive disease. In addition, there was evidence of colonic metastasis, a rare phenomenon in the setting of CCA ( 8 ), and one that has not been previously reported in LEL-CCA. Finally, although azathioprine is associated with EBV-positive lymphoproliferative disorders, neither it nor anti-TNF therapy has been shown to increase the risk of EBV-positive carcinoma ( 9,10 ).
In conclusion, we report a rare case of metastatic EBV-positive LEL-CCA in a young individual with IBD-PSC. Th is variant of CCA should be considered in the diff erential diagnosis for IBD-PSC patients with metastatic cancer and extensive intra-abdominal lymphadenopathy. Th orough investigation including imaging, histopathology, and endoscopic studies should be undertaken to establish the diagnosis. periods ( Figure 1 ). Measured and unmeasured confounding has been addressed using PERR.
CONFLICT OF INTEREST
In the adjusted analysis (net estimates, Figure 1 ) across the studied age-range, patients receiving PPIs were at greater risk of FF than controls (PERR-adjusted Hazard Ratio: 1.27: 95%CI: 1.16-1.34) aft er accounting for prior diff erences in FF rates. Th e Hazard Ratio for PPI use in those aged ≥85 overlapped with that in younger groups and were similar in patients with and without comorbidity. Sensitivity analyses excluding people with corticosteroids co-prescription and their matched pairs showed similar results (HR: 1.23, 95%CI: 1.05-1.44).
Since the hazard estimates were similar in age and comorbidity subgroups, subgroup-specifi c NNHs were calculated by applying the full-sample risk estimate to subgroup-specifi c FF rates ( 5 ) . Th e NNH for FF in all patients aged ≥60 was 121 (95%CI: 81 to 222) over 4 years. NNH in patients ≥85 (45, 30 to 81) was lower than that in ages 60-74 (207, 141 to 368) but similar in patients with and without comorbidity (data not shown).
Th is observational study, using a validated method to address unmeasured confounding, confi rms an ~30% increased FF risk in older patients receiving PPIs for ≥1 year. Although there were similar excess risks in patients aged ≥85, given the higher absolute risk of FF in this group, only 45 patients need to be treated to harm one, suggesting that PPIs should be used with caution especially for symptomatic relief in this group. In the UK, the vast majority of people aged ≥60 receive free drug prescriptions and the ≥1 year over-the-counter PPI use is therefore limited and unlikely to bias our results.
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